•
Dec 31, 2021
CryoPort Q4 2021 Earnings Report
Cryoport's Q4 2021 financial results were reported, showing revenue growth driven by Cryoport Systems and CRYOGENE.
Key Takeaways
Cryoport reported a 17% increase in revenue for Q4 2021, reaching $56.4 million. This growth was primarily driven by a 34% increase in organic revenue from Cryoport Systems and CRYOGENE. The company supports 602 clinical trials and 8 commercial therapies.
Q4 revenue reached $56.4 million, a 17% increase year-over-year.
Organic revenue from Cryoport Systems and CRYOGENE grew by 34%.
Cryoport supports 602 clinical trials and 8 commercial therapies globally.
Biopharma/Pharma revenue increased 18% year-over-year.
CryoPort
CryoPort
Forward Guidance
Cryoport anticipates up to nineteen additional filings, four new therapy approvals, and an additional six label or geographic expansion approvals in 2022.